Turning Point USA

European nations have started to reject the radical and experimental “gender affirming” model of care, which prescribes medications which stunt development and wreck hormones to children suffering from gender dysphoria.

“. . . countries such as Sweden, Finland, and England have made a clear U-turn away from some or all of these questionable protocols. After thoroughly reviewing the reliable evidence, these countries concluded that the risks of “gender-affirming care” far outweigh any potential benefits.”

Federalist

The concept of a medical transition only gained popularity within the past 15 years, the related medications and procedures are new enough to be deemed experimental, but are marketed to vulnerable individuals as safe, tried, and true — despite a number of devastating side effects. Many people, adults and children, who seek so-called gender affirming care are diagnosed with one or more mental illnesses, which should disqualify them from irreversible procedures, but unfortunately does not for a number of reasons.

First and foremost, hospitals and medial institutions have a significant profit incentive to prescribe “puberty blockers” (medications that were originally used to chemically castrate sex offenders), cross-sex hormones, and perform procedures such as a double-masectomy known as “top surgery,’ phalloplasty, and vaginoplasty, both are known as “bottom surgeries.”

This form of “care” differs from the method previously used for decades when encountering an individual suffering from gender incongruence. Historically (prior to about 15 years ago), medical professionals would encourage psychological care, rather than rushing confused people onto a medical conveyer belt of prescriptions and surgeries. Psychologists would affirm reality and objective truth, rather than the self-perceptions that the patient has created about themselves.

The procedures are themselves incredibly expensive, and can cost the patient anywhere from $10,000 to $40,000 to receive — not including the years of medications and follow-up care needed. The gender affirming care model creates lifelong dependents for the medical industrial complex.

“The U.S. sex reassignment surgery market size was valued at USD 1.9 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 11.23% from 2022 to 2030.”

“According to the 2021 annual report of the Mount Sinai Center for Transgender Medicine and Surgery, around 861 gender-affirming surgeries were performed at this hospital, wherein 639 surgeries were feminization procedures.”

Grand View Research

According to data provided by Grand View Research, the market for transgender surgeries is expected to grow 11.23% over the next 7 years — however the outlet fails to consider the possibility that the significantly increased rate of growth could be the result of a social contagion.

The U.S. has grown increasingly comfortable with the idea that an individual of a specific sex can undergo an invasive procedure to become whatever they identify with. Some cities even offer transgender residents monthly guaranteed income for being apart of the trendy new victim group. Only one hospital in the U.S. has publicly announced their plans to pause all gender transitions treatments after significant doctor and community backlash.

In contrast, Western European nations have started to press the breaks on the “care” which has been the subject of a number of lawsuits from severely harmed patients who looked to doctors for clarity and instead found medical abuse. NHS recently advocated against early social or medical transitioning, noting that most adolescents are going through a temporary and “transient” phase, and facilitating permanent change could case significant damage.

Some states have taken steps in the right direction by banning procedures on minors, however that is one small step of many that need to be taken to protect children and vulnerable individuals from medical industry greed.